NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) on behalf of long-term stockholders following a class action complaint that was filed against Kyverna on December 9, 2024 with a Class Period pursuant and/or traceable to the Company’s offering documents issued in connection with its initial public offering (“IPO”) conducted on February 8, 2024. Our in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ________________ Commission File Number: 001-41947 Kyverna Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware ...

EMERYVILLE, Calif., May 13, 2025– Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the quarter ended March 31, 2025. "We are pleased to report an exceptional start to the year, marked by rapid execution against our focused strategy to advance development of KYV-101 and build Kyverna into a robust clinical and commercial-ready organi ...

Enrollment complete in registrational Phase 2 KYV-101 trial in stiff person syndrome (SPS); on track for topline data in 1H 2026; biologics license application (BLA) filing now anticipated in 1H 2026 Advancing into registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) following successful end-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA); Phase 2 MG data anticipated in 2H 2025Company to host KOL event in Q3 2025, spotlighting its accelerating neuroinflammation franchise Strong fin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41947 Kyverna Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 83-1365411 (State or other jurisdict ...

Exhibit 99.1 Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis Fourth Quarter 2024 Highlights and Recent Business Updates KYV-101: Autologous, fully human CD19 CAR T-cell product candidate, incorporating highly potent CD28 co- stimulation. KYV-101 is currently being evaluated in company-sponsored KYSA trials and investigator- initiated tr ...

Core Insights - Kyverna Therapeutics is advancing its clinical programs for KYV-101, targeting stiff person syndrome, myasthenia gravis, and lupus nephritis, with a clear path to commercialization [2][7][17] - The company has aligned with the FDA on a registrational Phase 2 trial design for KYSA-8 in stiff person syndrome, with 70% enrollment completed and topline data expected in the first half of 2026 [7][11] - Financially, Kyverna reported $286 million in cash and equivalents as of December 31, 2024, providing a cash runway into 2027 [11][21] Clinical Development - KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate, currently in pivotal Phase 2 trials for stiff person syndrome and myasthenia gravis, and Phase 1/2 trials for lupus nephritis [3][15] - The company expects to report interim data from the Phase 2 trial in myasthenia gravis in the second half of 2025, and Phase 1 data from lupus nephritis trials in the same timeframe [6][7] - Kyverna is also exploring additional indications for KYV-101 through investigator-initiated trials across various autoimmune diseases [9][17] Financial Performance - For the year ended December 31, 2024, Kyverna reported a net loss of $127.5 million, or $3.33 per share, compared to a net loss of $60.4 million, or $89.61 per share, in 2023 [12][20] - Operating expenses increased significantly, with research and development costs rising to $112.5 million from $49.9 million in the previous year [20] - The company’s total assets as of December 31, 2024, were $304.6 million, a substantial increase from $75.2 million in 2023 [21] Strategic Initiatives - Kyverna has received multiple designations from the FDA, including Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation for its programs [7][8] - The company is strengthening its management team to support its growth strategy, with key appointments in executive roles [13] - Future plans include filing an investigational new drug application for KYV-102 in the second half of 2025, which aims to improve patient access to CAR T therapies [9][16]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Kyverna Therapeutics, Inc. (KYTX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by th ...

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to Kyverna’s initial public offering conducted on February 8, 2024 (the “IPO”), of the important February 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased Kyverna common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...